BOK Financial’s Mineralys Therapeutics MLYS Stock Holding History

BOK Financial’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-25	Closed	-$323	–	1403
2024 Q3	$323	Buy	+25	New	+$303	﹤0.01%	1280

Other funds holding MLYS

Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BOK Financial's MLYS Position: Q4 2024 in Review

BOK Financial sold out of Mineralys Therapeutics (MLYS) in Q4 2024, closing a stake of 25 shares — an estimated $323 sold.

BOK Financial first reported a position in MLYS in Q3 2024 and held it in 1 quarter. The position peaked at $323 in Q3 2024. 108 funds tracked by Wall St. Rank hold MLYS as of Q4 2024.

BOK Financial reported no remaining Mineralys Therapeutics position as of Q4 2024 after selling out during the quarter.
BOK Financial sold 25 Mineralys Therapeutics shares in Q4 2024, an estimated $323.
BOK Financial first reported a position in Mineralys Therapeutics in Q3 2024 and held it in 1 quarter.
BOK Financial's Mineralys Therapeutics position peaked at $323 in Q3 2024.
108 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q4 2024.

Based on BOK Financial's 13F filing for Q4 2024, filed 14 Feb 2025.